AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment

Source: Pharmacy Times articles

Dostarlimab in the neoadjuvant setting yielded a 100% clinical complete response in patients with rectal cancer.
Read More